Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company, celebrated its NYSE American listing with a Closing Bell ceremony on August 25, 2025. The company specializes in developing innovative intranasal products for emergency medical conditions.
Led by CEO Dan Teleman, Nasus Pharma is advancing its proprietary intranasal powder technology platform, focusing on treatments for severe allergic reactions and anaphylaxis. The company aims to provide needle-free, fast-acting alternatives to traditional emergency medications, particularly targeting families affected by anaphylaxis who currently rely on carrying Epinephrine.
Nasus Pharma (NYSE:NSRX), società farmaceutica in fase clinica, ha celebrato la sua quotazione alla NYSE American con la cerimonia del Closing Bell il 25 agosto 2025. L'azienda è specializzata nello sviluppo di prodotti intranasali innovativi per situazioni mediche di emergenza.
Guidata dall'Amministratore Delegato Dan Teleman, Nasus Pharma sta portando avanti la sua piattaforma proprietaria di tecnologia in polvere per somministrazione intranasale, concentrandosi su terapie per reazioni allergiche gravi e anafilassi. L'obiettivo è offrire alternative senza ago e ad azione rapida ai farmaci d'emergenza tradizionali, rivolgendosi in particolare alle famiglie colpite dall'anafilassi che oggi fanno affidamento sull'epinefrina da portare con sé.
Nasus Pharma (NYSE:NSRX), una compañía farmacéutica en fase clínica, celebró su incorporación en la NYSE American con la ceremonia del Closing Bell el 25 de agosto de 2025. La empresa se especializa en desarrollar productos intranasales innovadores para situaciones médicas de emergencia.
Bajo la dirección del CEO Dan Teleman, Nasus Pharma impulsa su plataforma propietaria de tecnología de polvo intranasal, centrándose en tratamientos para reacciones alérgicas graves y anafilaxia. La compañía busca ofrecer alternativas sin agujas y de acción rápida a los medicamentos de emergencia tradicionales, con un enfoque especial en las familias afectadas por la anafilaxia que actualmente dependen de llevar epinefrina.
Nasus Pharma (NYSE:NSRX)는 임상 단계의 제약사로, 2025년 8월 25일 NYSE American 상장 기념 Closing Bell 행사를 개최했습니다. 이 회사는 응급 의료 상황에 쓰이는 혁신적인 비강(코) 투여 제품을 개발하는 데 주력하고 있습니다.
CEO 댄 텔레만(Dan Teleman)이 이끄는 Nasus Pharma는 자사 고유의 분말형 비강 투여 기술 플랫폼을 발전시키며 중증 알레르기 반응 및 아나필락시스 치료에 집중하고 있습니다. 회사의 목표는 기존 응급 약물에 대한 바늘 없는 신속 작용 대안을 제공하는 것으로, 현재 에피네프린을 휴대해야 하는 아나필락시스 환자 가족을 특히 겨냥하고 있습니다.
Nasus Pharma (NYSE:NSRX), société pharmaceutique en phase clinique, a célébré son introduction sur la NYSE American par une cérémonie du Closing Bell le 25 août 2025. L'entreprise est spécialisée dans le développement de produits intranasaux innovants pour les situations médicales d'urgence.
Dirigée par le PDG Dan Teleman, Nasus Pharma fait progresser sa plateforme propriétaire de technologie de poudre intranasale, en se concentrant sur des traitements des réactions allergiques sévères et de l'anaphylaxie. L'objectif est de proposer des alternatives sans aiguille et à action rapide aux médicaments d'urgence traditionnels, en visant notamment les familles touchées par l'anaphylaxie qui dépendent aujourd'hui de l'épinéphrine à emporter.
Nasus Pharma (NYSE:NSRX), ein pharmazeutisches Unternehmen in der klinischen Phase, feierte am 25. August 2025 seine Notierung an der NYSE American mit einer Closing-Bell-Zeremonie. Das Unternehmen spezialisiert sich auf die Entwicklung innovativer intranasaler Produkte für medizinische Notfälle.
Unter der Leitung von CEO Dan Teleman treibt Nasus Pharma seine proprietäre Technologieplattform für intranasales Pulver voran und konzentriert sich auf Behandlungen bei schweren allergischen Reaktionen und Anaphylaxie. Ziel ist es, nadelfreie und schnell wirkende Alternativen zu herkömmlichen Notfallmedikamenten zu bieten, insbesondere für Familien, die wegen Anaphylaxie derzeit auf mitgeführte Epinephrin-Autoinjektoren angewiesen sind.
- None.
- None.
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, proudly announced today that it had the honor of ringing the Closing Bell on Monday, 25 August, 2025, at the New York Stock Exchange (“NYSE”). This prestigious event marked a significant milestone in the Company’s journey to transform emergency medicine through needle-free, fast-acting intranasal therapies.
Nasus Pharma’s executive team, board members, and key partners gathered on the NYSE podium to commemorate the Company’s progress and future ambitions. The ceremony recognized Nasus Pharma’s recent listing and celebrated the Company’s achievements in advancing its proprietary drug product candidates, designed to address critical unmet medical needs including severe allergic reactions and anaphylaxis.
“We are honored to participate in this iconic tradition at the NYSE. This moment reflects the incredible dedication of our team and our commitment to developing potentially life-saving treatments,” said Dan Teleman, Chief Executive Officer. “At Nasus Pharma, our mission is grounded in innovation. Our proprietary intranasal powder technology aims to offer a fundamentally better way to deliver life-saving medications. This platform could have broad potential across emergency care, and we believe that we are just beginning to unlock it. At the center of everything we do is our care for patients. We are aiming to develop solutions that are fast, easy to use, and ready when they’re needed most, and currently focus on helping families who live with the fear of anaphylaxis every day who have to carry Epinephrine wherever they go, who worry about what could happen in a moment of exposure to allergens. That’s our purpose: to give families peace of mind, to give patients more accurate control, and to make a difference when seconds count.”
A replay of the event can be found here and on Nasus Pharma’s Investor Relations Events page.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: the development and commercialization, if any, of any other product candidates that we develop or may seek to develop, the potential of Nasus Pharma’s proprietary intranasal powder technology. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the initial public offering filed with the SEC on August 14, 2025. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Contact
info@nasuspharma.com
Nasus Pharma Ltd. Israel
https://www.nasuspharma.com
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
FAQ
When did Nasus Pharma (NSRX) ring the NYSE American Closing Bell?
What type of medical products does Nasus Pharma (NSRX) develop?
Who is the CEO of Nasus Pharma (NSRX)?
What is Nasus Pharma's (NSRX) main product focus?
Where can investors watch the replay of Nasus Pharma's NYSE bell ringing ceremony?
